A multicenter phase II study of Nivolumab monotherapy in recurrent and/or metastatic gastrointestinal cancer patients with high Tumor Mutation Burden (TMB-H)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms bTMB-High Basket trial; TMB-H basket
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium.
- 19 Sep 2018 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 New trial record